Background: This open-label, randomised phase III study was designed to further investigate the clinical activity and safety of SRL172 (killed Mycobacterium vaccae suspension) with chemotherapy in the treatment of non-small-cell lung cancer (NSCLC).
Introduction
Lung cancer is the most common cancer globally with >1 million new cases recorded each year [1] . About 80% of lung cancer cases are classified as non-small-cell lung cancer (NSCLC) . Approximately 30-40% of all patients with NSCLC have locally unresectable disease at the time of initial diagnosis (stage IIIa and stage IIIb) and 40-50% of all lung cancer patients have metastases at first presentation (stage IV) [2] . Patients presenting with late-stage disease (stage III or IV) have a poor prognosis with an overall 5-year survival rate of ∼5% in England and Wales, and 9% in Europe [3] . Despite changes in primary treatments, the mortality rates for patients with NSCLC have not improved significantly in the past 20 years [4] .
Although advanced-stage NSCLC (stage IIIb/IV) remains a non-curable disease, chemotherapy has been shown to increase symptom control, improve quality of life, be cost-effective and increase survival rates (median and 1-year) [5] . Most patients newly diagnosed with late-stage NSCLC and a good performance status will be treated with chemotherapy. Modern platinum combination chemotherapy regimens produced an overall response rate of ∼20% with a median survival of 7.9 months and 1-year survival of 33% [6] . In the UK MIC2 study, chemotherapy provided overall response rates of 33%, 1-year survival of 26% and median survival of ∼7 months [7] .
SRL172 is a suspension of killed Mycobacterium vaccae, a rapidly growing mycobacterium that normally grows as an environmental saprophyte. It has several functions relevant to its activity in cancer, including activation of antigen-presenting cells (APCs), Th1 adjuvant properties, suppression of pre-existing Th2 responses (via activation of regulatory T cells), and activation of natural killer (NK) cells [8] . A switch to a Th2 cytokine profile in cancer has been described, for example, in colorectal cancer [9] , NSCLC [10] and small-cell lung cancer (SCLC) [11] .
The activity of SRL172 in various forms of cancer has been suggested in a number of phase I and II clinical studies in malignant melanoma [12] , mesothelioma [8] and prostate cancer [13] . This current study was designed following initial results suggesting a 29% survival benefit in a small randomised phase II study in NSCLC [14] and a similar result in SCLC [15] . These studies raised the possibility of synergy between chemotherapy and SRL172. This trial aimed to investigate the efficacy and safety of SRL172 in the treatment of patients with surgically unresectable locally advanced or metastatic NSCLC, when given in addition to standard chemotherapy.
Patients and methods

Study design
The study design was based on experience gained from previous phase I/II studies conducted with SRL172. The study was designed as a randomised but open trial as SRL172 is a suspension and most patients develop a delayed-type hypersensitivity reaction at the injection site, making the use of a matching placebo difficult. Since the primary end point was overall survival, observer bias was considered to be negligible. In addition, randomisation was blinded, thereby avoiding bias in the allocation of individual patients to treatment. Patients were stratified by extent of disease as either surgically unresectable stage IIIa, or stage IIIb/IV (palliative treatment). The study was conducted at a total of 28 sites in four countries: Austria (three sites), Germany (five sites), Poland (four sites) and the UK (16 sites).
The protocol and its amendments were approved by the appropriate Independent Ethics Committee (IEC) for each participating centre. The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) and with the principles stated in the Declaration of Helsinki. Written informed consent was obtained from all patients.
Patient selection
Male or female patients aged at least 18 years, with histologically and/or cytologically confirmed unresectable NSCLC (stages IIIa, IIIb and IV) were eligible for the study. Patients were to have measurable lesions in at least one site, which had not been previously irradiated, an European Organisation for Research and Treatment of Cancer-World Health Organisation (EORTC-WHO) performance status of <2 and life expectancy of >3 months in the opinion of the investigator.
Patients were excluded if they had severe, active, uncontrolled infection requiring systemic antibiotics, antivirals or antifungals; if they had received previous chemotherapy for NSCLC; if they had evidence of central nervous system (CNS) metastases or if they had any previous or concurrent malignancy (except adequately treated carcinoma in situ of the cervix, basal cell carcinoma of the skin and/or non-melanoma skin cancer or if previous malignancy was more than 5 years prior and there were no signs of recurrence). They must not have received depot corticosteroids in the 6 weeks prior to day 0 or chronic systemic corticosteroids in the 2 weeks prior to administration of the study drug. Patients who had previously received SRL172 were also excluded.
Treatment schedule
Patients were screened to ensure that 400 evaluable patients were enrolled. Following a screening period of up to 28 days, those who fulfilled the entry criteria and had given written informed consent were stratified by extent of disease as either surgically unresectable stage IIIa or stage IIIb/IV. These patients were then randomised to receive either chemotherapy alone or chemotherapy plus SRL172. Chemotherapy consisted of up to six cycles of MVP [mitomycin C 8-10 mg/m 2 ; vinblastine 6 mg/m 2 (max 10 mg) and cisplatin 50-120 mg/m 2 or carboplatin AUC of 4-6 (mg/ml × min) × (EDTA + 25)] on day 0 and weeks 3, 6, 9, 12 and 15 . The doses used were according to the standard protocol at each centre, and mitomycin C was excluded at cycles three and five.
SRL172 administration
SRL172 (a suspension of heat-killed M. vaccae NCTC 11659) was supplied in borate-buffered saline at pH 8, 0.1 ml of which contained 1 mg wet weight corresponding to 10 9 bacilli. A dose of 0.1 ml was given intradermally over the deltoid muscle on day 0 and weeks 4, 8, 12 and 16 during the treatment phase. The vials of SRL172 were supplied and kept in refrigrators at 4°C. The four phases of the study are illustrated in Figure 1 . If there was no disease progression after the initial treatment phase, patients randomised to receive SRL172 entered a maintenance and follow-up phase, during which they could continue to receive SRL172 and were clinically assessed every 8 weeks, until there was clear evidence of disease progression. The patients randomised to receive chemotherapy alone entered a follow-up phase during which they were clinically assessed every 8 weeks, until there was clear evidence of disease progression. After disease progression, patients entered the survival phase of the study during which they were clinically assessed every 12 weeks.
Evaluation criteria
Overall survival (time from randomisation to death) was the primary end point of the study. Secondary efficacy variables included the proportion of patients who were alive 1 year after randomisation, various tumour response parameters, proportion of patients suitable for treatment downstaging after completion of study medication, progression-free survival and subgroup analysis as appropriate. Safety criteria related to disease, chemotherapy and SRL172 were also evaluated. In addition, treatment differences in health-related quality of life were investigated for the treatment and maintenance phases combined and treatment differences in health-related quality of life for the treatment phase, maintenance and survival phase and the end-of-study.
Statistical analysis
Survival. The sample size requirements for this study were based on the comparison planned for the primary efficacy parameter, overall survival time. Preliminary results from a pilot study [14] indicated an increase in median overall survival time from 7 months (MVP-treated patients) to 9.5 months (MVP plus SRL172), i.e. a median survival time ratio of ∼1.4. Estimates from the literature suggested a 1-year survival rate for MVP-treated patients of ∼10%. Combining these estimates yielded an estimated 1-year survival rate for chemotherapy plus SRL172 patients of ∼20%. Thus, allowing for a 10% drop out, 80% power and a significance level of 0.02; 200 patients per group (i.e. 400 evaluable patients) were enrolled into the study.
The overall survival curves were compared using a stratified Mantel Haenszel test and Kaplan-Meier plots of the survival times were performed. The analyses used all information up to the date of death. Patients were censored at the last date they were known to be alive (i.e. last assessment date). Each disease stage was also analysed separately in the same manner. Dichotomous efficacy variables (i.e. proportions of patients with an event) were compared between treatment groups using Fisher's exact test and corresponding 95% confidence interval. Time-to-event variables were compared between treatment groups using a Mantel Haenszel test, with presentation of summary statistics derived from Kaplan-Meier estimates. Duration of event variables were compared between treatment groups using a Wilcoxon rank sum test.
Summary statistics were generated for other efficacy and safety variables. Additional exploratory analyses were conducted, using accelerated failure Quality of life. The Global Health Status scale was the primary scale examined for significant treatment differences at the 0.05 level of significance. The null hypothesis was that there was no statistical difference between active treatment groups. Individual scale scores were examined for differences, adjusting for multiplicity using the Hochberg-Benjamini sequential testing procedure. EORTC assessments were scored according to standard rules as described in the EORTC QLQ-C30 (EORTC Quality of Life Questionnaire-Core 30) Scoring Manual [16] . All of the scales and single-item measures ranged in score from 0 to 100. A high scale score represented a higher response level (e.g. high score for a functional scale represented a high level of functioning and a high score for a symptom scale represented a high level of symptomatology/problems). The primary quality of life analysis was the evaluation of longitudinal scores in the chemotherapy plus SRL172 group, compared with the chemotherapy alone group using generalised estimating equations, adjusting for covariates.
Results
Demographic data
The demographic data at screening for all randomised patients is summarised in Table 1, whilst Table 2 summarises the key data regarding NSCLC history. Examination of demographic and other baseline data did not reveal any clinically relevant differences between the treatment groups.
A total of 210 patients were randomised to receive chemotherapy plus SRL172 and 209 patients were randomised to receive chemotherapy alone. Evaluable patients were defined as those who were randomised to receive study drug, received at least one administration of either the standard chemotherapy regimen (208 patients) and/or at least one administration of SRL172 (208 patients), had NSCLC and reported data for analysis. Data from patients who became ineligible for the study were censored at the time of protocol violation or deviation. The majority of patients enrolled were male (71% overall) and the median age was 61 years. The most frequent histology, reflecting the fact that this was a European study, was squamous cell carcinoma (41%), followed by adenocarcinoma (35%), large cell carcinoma (13%) and other types of carcinoma (11%) [8] .
Primary efficacy analysis
The primary efficacy end point for this study was overall survival. The Kaplan-Meier plot of overall survival is presented in Figure 2 . No difference was observed between the treatment groups in overall survival, with a median survival time of 223 days in the chemotherapy plus SRL172 group, compared to 225 days in the chemotherapy alone group (P = 0.65).
There was a trend towards a higher proportion of patients alive at the end of the 15-week treatment phase (Figure 2 ) in the chemotherapy plus SRL172 group (90%) than in the chemotherapy alone group (83%, P = 0.061).
In this context it is of note that only 46% of patients randomised to the chemotherapy plus SRL172 group received the scheduled number of doses during the treatment phase and 63% of patients did not receive any further injections of SRL172 after the end of the 15-week treatment phase. The mean number of SRL172 injections overall was 4.7 for all patients in the SRL172 group. Also, only 27% of patients in the chemotherapy plus SRL172 group and 28% of patients in the chemotherapy alone group received six courses of MVP. Seventy-seven per cent of patients received three or more MVP courses in this study.
Secondary efficacy analyses
The results from the secondary efficacy analyses were in general in accordance with the results of the primary analysis. None of the prospectively defined secondary efficacy analyses were statistically significant, although there was a trend towards improved time to progression for the chemotherapy plus SRL172 group compared to the chemotherapy alone group (158 days versus 135 days, P = 0.1556).
Overall, in each of the treatment groups, 26% of patients were alive at 1 year. There was a slightly higher proportion of patients alive at the end of the 15-week treatment phase in the chemotherapy plus SRL172 group (186 patients, 90%), than in the ). This difference just failed to achieve statistical significance (P = 0.061). Similar proportions of patients in each treatment group had an objective tumour response during the study (chemotherapy plus SRL172, 37%; chemotherapy alone, 33%) (P = 0.413). There was no significant difference between the treatment groups in the time to an objective tumour response. The median time from objective tumour response to progression was 172 days in the chemotherapy plus SRL172 group and 150 days in the chemotherapy alone group (P = 0.1653). There was no difference between the treatment groups in the time from disease progression to death.
There was no statistically significant difference in survival in different subgroups (male versus female and performance status 0/1 versus 2), although a trend was seen in adenocarcinomas (193 days survival with chemotherapy plus SRL172 compared with 154 days for chemotherapy alone; P = 0.10, 144 patients).
Quality of life
At the end of the 15-week treatment phase, there was a statistically significant difference in the mean change from baseline in the primary quality of life variable, Global Health Status, between the treatment groups (adjusted P-value 0.002), with patients in the chemotherapy alone group (172 patients) having a greater deterioration in their Global Health Status score (-14. 3) than patients in the chemotherapy plus SRL172 group (179 patients) (-6.6) . Two methods were used in the analysis: Multiple Imputational Analysis (MIA) (43% imputed) and Last Observation Carried Forward (LOCF) (39% carried forward). Both techniques gave similar results.
Mean changes from baseline (179 patients) in EORTC QLQ-C30 composite scores in the chemotherapy plus SRL172 group, compared to the chemotherapy alone group, at the end of the treatment phase are presented in Table 3 . Missing values in this analysis were accounted for by MIA. Statistically significant differences at the end of the treatment phase were noted in favour of the chemotherapy plus SRL172 group in all other composite components of the QLQ-C30 questionnaire, except 'role limited due to physical problems' and 'social functioning' where differences were not statistically significant. Statistically significant differences at the end of the treatment phase were also noted in favour of the chemotherapy plus SRL172 group for many of the single items on the QLQ-C30 questionnaire.
By the end of the maintenance and survival phase, the differences observed at the end of the treatment phase in favour of the chemotherapy plus SRL172 group had diminished. Only subjects who had completed the treatment and maintenance phases and then entered the survival phase were included in this analysis. Hence sample sizes were small (chemotherapy alone, 28 patients; chemotherapy plus SRL172, 38 patients), resulting in a lack of statistical power in the MIA analyses. However, using the LOCFimputed data, there was a statistically significant difference between treatments in favour of the chemotherapy plus SRL172 group for the primary parameter of Global Health Status, during the treatment and maintenance phase. Mean changes from baseline in scores from the EORTC QLQ-LC13 lung module, in the chemotherapy plus SRL172 group compared to the chemotherapy Table 4 .
At the end of the treatment phase, patients' scores on all components of the QLQ-LC13 questionnaire had worsened from baseline in both treatment groups, as illustrated for the primary parameter of Global Health Status in Figure 3 . However, the deterioration was less pronounced for the chemotherapy plus SRL172 group and treatment differences (adjusted) were statistically significant for sore mouth, dysphagia and peripheral neuropathy.
Safety analyses
A total of 192 patients (91.4%) in the chemotherapy plus SRL172 group reported at least one on-treatment, non-serious adverse event (AE) compared with 177 patients (84.7%) in the chemotherapy alone group. One hundred and six patients (50.5%) in the chemotherapy plus SRL172 group reported at least one ontreatment serious adverse event (SAE), versus 80 patients (38.3%) in the chemotherapy alone group. In total, 1229 treatment emergent events (AE and SAE) were reported in the chemotherapy plus SRL172 group compared with 1034 events in the chemotherapy alone group.
The most frequently occurring events (serious and non-serious) in both treatment groups were anaemia, leucopenia and thrombocytopenia, which were reported by 33.8%, 26.2% and 22.9% of patients in the chemotherapy plus SRL172 group and 25.8%, 23.4% and 16.3% of patients in the chemotherapy alone group, respectively. The differences were not statistically significant. Table 3 . Analysis at end of 15-week treatment phase on composite scores from EORTC QLQ-C30 (multiple imputation) a Mean change and P values adjusted for age, sex, current smoking status, cancer stage, weight loss and country. Mean change also adjusted for baseline. Note: for Global Health Status and the functioning parameters (parameters 1-6 above), a decrease from baseline indicates worsening. For the symptom parameters (parameters 7-9 above), a decrease from baseline indicates improvement. For all parameters except Global Health Status, the P values presented are the Hochberg-Benjamini P values. The majority of these types of events were considered by the investigator not to be related to SRL172. A total of 35 patients (16.7%) in the chemotherapy plus SRL172 group reported an injection site reaction. However, in the majority of cases injection site reactions were of a mild intensity, with severe reactions reported in only two patients (1%) overall. There were more patients with NSCLC in the chemotherapy plus SRL172 group who reported chest pain (11%) than in the chemotherapy alone group (4%). However, only one case of chest pain in the chemotherapy plus SRL172 group was considered to be severe, compared to two cases in the chemotherapy alone group. None of the cases of chest pain were considered by the investigator to be related to study medication. No significant differences between treatment groups were observed in the incidence of abnormal laboratory values, vital signs, physical examination, tumour-related symptoms or chemotherapy toxicities.
Discussion
The overall results of the study did not show any difference in survival between those patients receiving standard chemotherapy and those additionally receiving SRL172, despite a survival trend in favour of the combined treatment group during the 15-week treatment phase (90% versus 83%, P = 0.061) and improved quality of life in the combined group. These results do not confirm those suggested in a small randomised phase II study [14] of 29 patients with symptomatic advanced NSCLC or mesothelioma but indicate that SRL172 was exerting an effect only as long as treatment was maintained. SRL172 did appear to be associated with small, non-statistically significant effects on survival time in adenocarcinoma patients.
Quality of life measures showed an improvement in performance status (for example cognitive functioning and vitality), a reduction in treatment-related adverse effects (including nausea and vomiting and peripheral neuropathy) and relief of cancer- related symptoms (such as bodily pain and dyspnoea) in those additionally receiving SRL172, compared with the chemotherapy alone group (Tables 3 and 4 ). These improvements in quality of life in the terminal stages of NSCLC may be important given the many concerns regarding the administration of cancer chemotherapy in advanced disease including toxicity, the perceived high cost of treatment [17] , the low response rate and moderate impact on long-term survival [7] . Unfortunately, in this study only 30 patients (14%) received one or more SRL172 injections after the treatment phase. This is due to the high drop out in NSCLC studies due to early progressive disease of the order of 50% at 5 months, i.e. at the end of the 15-week treatment phase. Sixty-three per cent of patients did not receive any further injections of SRL172 after the end of the 15-week treatment phase. It is possible that a greater effect of SRL172 might have been observed if a more intensive treatment schedule had been used particularly after the treatment phase.
Results from a phase II study of SRL172 in renal cell cancer, in which patients did not receive any chemotherapy and continued with SRL172 throughout follow-up, suggested that monotherapy with SRL172 may offer a similar survival benefit to that conferred by established biological treatments in patients with renal cancer [18] .
Safety assessments showed few differences between treatment groups. Although adverse effects were slightly higher with SRL172 and chemotherapy, this was not statistically significant and was likely to be due to increased reporting of the SRL172 plus chemotherapy arm in this non-blinded study. The combination of chemotherapy and SRL172 was well tolerated with mild injection site reactions occurring in 17% of SRL172 patients.
The results from this study suggest that further work with patients in whom chemotherapy treatment is completed or not warranted, would be of interest and would require a placebo control to confirm the quality of life findings. Also, treatment should be given more frequently and/or continued for a longer period.
